安宫牛黄丸通过改善肠道菌群失调减轻小鼠脑缺血再灌注损伤
该研究建立小鼠大脑中动脉闭塞(MCAO)模型,对盲肠内容物进行16S rRNA基因测序和代谢组学分析,发现安宫牛黄丸可缩小脑梗死体积、改善神经功能缺损并减轻组织病理损伤,同时逆转肠道菌群失调并调节炎症与神经保护相关代谢物。
要点
- 安宫牛黄丸可减轻MCAO小鼠脑梗死体积和神经功能缺损。
- 安宫牛黄丸可逆转肠道菌群失调并调节相关代谢物。
- 尿苷、鸟苷、肌苷可能是安宫牛黄丸治疗组肠道菌群产生的潜在神经调节物。
核心结论
- 缓解肠道菌群失调是安宫牛黄丸保护缺血性卒中的机制之一。
- 靶向Alloprevotella、Lachnoclostridium、Enterorhabdus、Roseburia、Lachnospiraceae_UCG-006和Colidextribacter可能是潜在的抗卒中治疗策略。
研究设计与样本
- 研究采用小鼠大脑中动脉闭塞(MCAO)模型,设假手术组、模型组和安宫牛黄丸治疗组。
- 对盲肠内容物样本进行16S rRNA基因测序和代谢组学分析。
主要发现
- 安宫牛黄丸显著减轻脑梗死体积、改善神经功能缺损并减少同侧缺血皮层、海马和纹状体的组织病理损伤。
- 上述作用包括抑制神经元死亡、增加尼氏体 and 减少细胞凋亡。
- 安宫牛黄丸调节拟杆菌门和厚壁菌门、毛螺菌科和普雷沃氏菌科、Alloprevotella和Roseburia等菌属的丰度。
- 安宫牛黄丸调节前列腺素I2和尿苷等与炎症和神经保护相关的微生物代谢物。
- Spearman相关分析显示这些代谢物与Alloprevotella、Lachnoclostridium、Enterorhabdus、Roseburia、Lachnospiraceae_UCG-006和Colidextribacter等菌属密切相关。
临床怎么用
- 安宫牛黄丸治疗缺血性卒中的机制可能部分通过调节肠道菌群及其代谢物实现。
- 临床可关注肠道菌群作为安宫牛黄丸治疗卒中的潜在干预靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Angong Niuhuang Pill (ANP) is a famous traditional Chinese patent medicine and is used for treating ischemic or hemorrhagic stroke for centuries. However, the mechanism of action of ANP in stroke treatment has rarely been reported. With increasing evidence for a mechanistic link between acute ischemic stroke and gut microbiota alterations, this study aimed to determine the mechanism of action of ANP in treating acute ischemic stroke from the perspective of the gut microbiota. A mouse model of acute ischemic stroke by middle cerebral artery occlusion (MCAO) was established, and 16S ribosomal RNA (rRNA) gene sequencing and metabolomic analysis were performed on the cecal content samples collected from the sham, model, and ANP-treated MCAO mice. The results showed that ANP significantly ameliorated cerebral infarct volume, improved neurological deficits, and reduced histopathological injuries in the ipsilateral ischemic cortex, hippocampus, and striatum. The latter effects included inhibition of neuronal death, increased Nissl bodies, and decreased cell apoptosis. Moreover, ANP reversed gut microbiota dysbiosis by modulating the abundance of bacteria whose effects may mitigate MCAO damage, such as the phyla Bacteroidetes and Firmicutes, the families Lachnospiraceae and Prevotellaceae, and the genera Alloprevotella and Roseburia. Microbial metabolites related to inflammation and neuroprotection, such as prostaglandin I2 and uridine, were also regulated by ANP treatment. Uridine, guanosine, and inosine might be potential neuromodulators produced by the gut microbiota in the ANP-treated group. Spearman correlation analysis revealed that these metabolites were intimately related to certain genera, including Alloprevotella, Lachnoclostridium, Enterorhabdus, Roseburia, Lachnospiraceae_UCG-006, and Colidextribacter. Our results demonstrated that alleviating gut microbiota dysbiosis is one of the mechanisms by which ANP protects against ischemic stroke and suggest that targeting Alloprevotella, Lachnoclostridium, Enterorhabdus, Roseburia, Lachnospiraceae_UCG-006, and Colidextribacter might be a potential anti-stroke therapy.
引用
- Zhang H, Hui X, Wang Y, et al. Angong Niuhuang Pill ameliorates cerebral ischemia/reperfusion injury in mice partly by restoring gut microbiota dysbiosis. Front Pharmacol. 2022. PMID: 36188565. doi:10.3389/fphar.2022.1001422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。